|Other Names||Liprin-alpha-1, LAR-interacting protein 1, LIP-1, Protein tyrosine phosphatase receptor type f polypeptide-interacting protein alpha-1, PTPRF-interacting protein alpha-1, PPFIA1, LIP1|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May regulate the disassembly of focal adhesions. May localize receptor-like tyrosine phosphatases type 2A at specific sites on the plasma membrane, possibly regulating their interaction with the extracellular environment and their association with substrates.|
|Cellular Location||Cytoplasm. Note=Colocalizes with PTPRF at the ends of focal adhesions most proximal to the cell nucleus|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a member of the LARprotein-tyrosine phosphatase-interacting protein (liprin) family.Liprins interact with members of LAR family of transmembraneprotein tyrosine phosphatases, which are known to be important foraxon guidance and mammary gland development. This protein binds tothe intracellular membrane-distal phosphatase domain of tyrosinephosphatase LAR, and appears to localize LAR to cell focaladhesions. This interaction may regulate the disassembly of focaladhesion and thus help orchestrate cell-matrix interactions.Alternatively spliced transcript variants encoding distinctisoforms have been described.
Asperti, C., et al. Exp. Cell Res. 316(6):915-926(2010)Dancau, A.M., et al. Genes Chromosomes Cancer 49(1):1-8(2010)Asperti, C., et al. J. Cell. Sci. 122 (PT 18), 3225-3232 (2009) :Venkatesan, K., et al. Nat. Methods 6(1):83-90(2009)Tan, K.D., et al. Genes Chromosomes Cancer 47(4):353-362(2008)
If you have any additional inquiries please email technical services at email@example.com.